01 What is Survodutide?
In plain English.
Survodutide is an experimental once-weekly injection being developed by Boehringer Ingelheim with Zealand Pharma for obesity and liver disease. It is a single engineered molecule that switches on two different hormone receptors at once: the GLP-1 receptor (the same target as Wegovy and Ozempic) and the glucagon receptor. The GLP-1 arm reduces appetite; the glucagon arm is thought to raise the rate at which the body burns energy and to help clear fat out of the liver. It was previously known by its development code BI 456906.
It is currently investigational, meaning it is not available as a prescription medicine anywhere in the world. The only legitimate route to receive it today is enrolment in a registered clinical trial. Anything labelled 'survodutide' or 'BI 456906' on a research-chemical site is unregulated and unverifiable, and there is no approved product to compare it against.
02 How it works
The simple version, then the science.
Survodutide is a single molecule designed to act on two receptors. The first, the GLP-1 receptor, is the well-known appetite target shared with semaglutide: switching it on slows the stomach, blunts hunger and improves blood-sugar control. The second, the glucagon receptor, is the novel part. Glucagon normally raises blood sugar, but in the right balance its signalling also pushes the body to spend more energy and to break down fat stored in the liver. The bet behind survodutide is that combining appetite suppression with higher energy expenditure produces more weight loss, and directly targeting liver fat makes it useful in fatty-liver disease (MASH).
Go deeper · the proposed mechanism
Survodutide is a long-acting acylated peptide engineered as a balanced co-agonist of the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R), with albumin-binding via a fatty-acid side chain extending the half-life to roughly one week for once-weekly subcutaneous dosing. The GLP-1R arm drives the familiar effects: delayed gastric emptying, central anorectic signalling and glucose-dependent insulinotropic action. The GCGR arm is the differentiator: hepatic glucagon-receptor agonism is thought to increase resting energy expenditure and lipid oxidation, and to drive intrahepatic fat mobilisation and reduced steatosis — the rationale for the MASH programme. Balancing the two agonist potencies matters, because excess glucagon signalling can raise glucose and heart rate; titration is used to manage this. This dual-incretin/glucagon design places survodutide alongside retatrutide (a triple GIP/GLP-1/glucagon agonist) in the next wave of metabolic peptides.
03 What it's used for
Each use graded by how strong the evidence actually is.
- ModerateObesity / weight loss🔬 A phase 2 dose-finding trial in adults with overweight or obesity (le Roux et al., The Lancet, 2024; ~387 participants) reported dose-dependent mean weight loss of roughly 15% at 46 weeks on the highest doses, with a clear dose-response. Promising, but phase 2 — the pivotal phase 3 obesity programme is ongoing and survodutide is not approved.
- ModerateMASH (metabolic dysfunction-associated steatohepatitis)🔬 A phase 2 trial in biopsy-confirmed MASH (Sanyal et al., New England Journal of Medicine, 2024) reported that up to ~83% of participants on survodutide achieved improvement in MASH versus ~18% on placebo, with reductions in liver fat. This is among the most notable phase 2 MASH signals to date, but it is a single phase 2 trial; confirmatory phase 3 work is required.
- LimitedLiver fibrosis improvement🔬 In the same phase 2 MASH trial, more participants on survodutide than placebo showed improvement in liver fibrosis without worsening of MASH. The fibrosis signal is encouraging but secondary and underpowered for firm conclusions; fibrosis endpoints are the hard test that phase 3 must confirm.
- AnecdotalOnline "research chemical" weight-loss use💬 Vials labelled "survodutide" or "BI 456906" are sold by unregulated peptide vendors. Contents, purity, sterility and dose accuracy are unverifiable, there is no clinical oversight, and no approved product exists to compare against.
04 What the evidence says
Survodutide's evidence base is genuinely promising but still early. In obesity, the phase 2 dose-finding trial (le Roux et al., The Lancet, 2024) established a clean dose-response and produced mean weight loss in the mid-teens of percent at the highest doses over roughly 46 weeks — competitive with the dual-agonist class. In liver disease, the phase 2 MASH trial (Sanyal et al., NEJM, 2024) is the headline result: a large majority of treated participants achieved histological improvement in MASH versus a small minority on placebo, with encouraging signals on liver fat and fibrosis. Two honest caveats. First, every one of these is a phase 2 trial — dose-finding and signal-seeking, not pivotal. The phase 3 obesity and MASH programmes are ongoing and have not read out, and biopsy-based liver endpoints in particular have a history of looking better in phase 2 than they hold up in phase 3. Second, the glucagon arm that gives survodutide its distinctive energy-expenditure and liver-fat effects also raises plausible cardiovascular and glycaemic questions (heart rate, glucose) that only larger, longer trials can settle. The fair description today is 'strong phase 2 signals in two indications, unapproved, and not yet population-tested' — the same maturity as cagrilintide and retatrutide.
05 Dosing & administration
Reported in the literature, information not advice.
For context only. There is no approved survodutide product and no validated outpatient protocol. Trial protocols use once-weekly subcutaneous injection with a slow titration over several months, stepping up through low starting doses to a target dose, specifically to manage gastrointestinal side effects and the heart-rate effects associated with the glucagon arm. Different doses have been studied in the obesity and MASH programmes. None of this is an instruction: self-dosing from unregulated suppliers sits outside the boundary of established medicine and cannot be made safe by following a forum protocol.
06 Side effects & safety
In phase 2 trials the most common adverse events were gastrointestinal — nausea, vomiting, diarrhoea and constipation — typically worst during dose escalation and easing afterwards, as with the wider GLP-1 class. The distinctive safety consideration is the glucagon receptor arm: glucagon agonism can increase heart rate and, by raising blood sugar, partially offset glycaemic benefit, which is one reason trials titrate the dose slowly. Injection-site reactions are reported. Long-term cardiovascular safety, effects in people with established heart disease, and durability beyond the phase 2 windows are not yet characterised. Typical trial exclusions for this class include pregnancy and breastfeeding, personal or family history of medullary thyroid cancer or MEN-2, active pancreatitis and severe gastrointestinal disease. The quality of any non-trial 'survodutide' bought online is entirely unknown.
07 Can you buy it?
Investigational, not approved or sold as a medicine anywhere.
08 Legal & regulatory status
- UKNot licensed by the MHRA. Available only via clinical trial participation. No legitimate UK supply outside trials.
- USNot FDA-approved. Phase 3 trials in progress; no compounding pathway because no approved survodutide product exists.
- EUNot authorised by the EMA. Investigational only.
- SportSurvodutide is not named individually on the WADA Prohibited List, but as an unapproved investigational substance it is captured by category S0 ("Non-Approved Substances") and is prohibited at all times in tested sport.
09 Clinical studies & research
Primary sources. Read the science yourself.